News | June 03, 2022
Evonik to build new lipid production facility for mRNA-based therapies in U.S.
Construction will begin in early 2023, and the plant is scheduled to go onstream in 2025
Construction will begin in early 2023, and the plant is scheduled to go onstream in 2025
The study was conducted in equal laboratory conditions in the Spallanzani Institute in Italy on comparable sera samples from individuals vaccinated with Sputnik V and Pfizer with a similar level of IgG antibodies and virus-neutralizing activity (VNA) against Wuhan variant.
Approval follows CHMP recommendation for use in patients previously vaccinated with Vaxzevria or an EU-approved mRNA Covid-19 vaccine
Union Minister of State for Science and Technology, Dr Jitendra Singh gave the award for the successful commercialization of indigenous technology on National Technology Day 2022
The move comes a few weeks after receiving the EUA for children between the ages of 5 and 12
The mRNA vaccine candidate is fully indigenous and devoid of any technology contributions from elsewhere
AKS-452 is currently undergoing Phase II/III clinical testing in India as a primary vaccine; submission for Emergency Use Authorization (EUA) expected by Q3 2022
CEPI will provide funding of up to US $19.3 million to support the development of a ‘variant-proof’ SARS-CoV-2 vaccine candidate to an international multidisciplinary consortium
Novel approach driven by GN Corp Japan with potentials in neurological illnesses
The research was supported by the BGU Coronavirus Challenge and the Israeli Ministry of Health.
Subscribe To Our Newsletter & Stay Updated
